Crimean-Congo Hemorrhagic Fever Study

794
Map
Crimean-Congo Hemorrhagic Fever Study
United States of America
To research the nairovirus, Crimean-Congo hemorrhagic fever, a tick-borne viral disease, especially common in East and West Africa. With mortality rates as high as 80 percent and with no FDA approved vaccines or therapeutics, Crimean-Congo hemorrhagic fever is considered a dangerous pathogen and a serious bioterrorism threat. The project will expand the knowledge of the ovarian tumor protease domain of the nairovirus to inform control measures and vaccine development.
University of Georgia (National Institutes of Health)
CDC's National Center for Emerging and Zoonotic Infectious Diseases

The Business Case for Global Health Security

Read more

Conference Celebrates Public Health Success and Needs in Africa

Read more

Disease Outbreaks Create Real Business Challenges

Read more

One Interconnected World That Needs Protection

Read more

A Time to Take Stock and Look Ahead

Read more

CDC Foundation Receives $13.5 Million in Grants for Global Health

Read more

CDC puts research into practice to advance public health, save lives

Read more
Subscribe to Global Health Security